Literature DB >> 17504652

Patent foramen ovale and migraine.

Hans-Christoph Diener1, Tobias Kurth, David Dodick.   

Abstract

Results from several observational studies indicate an association between migraine and patent foramen ovale (PFO). Several biological mechanisms have been proposed to explain this link, including shared genetic inheritance. However, there is currently insufficient evidence to support a causal link between PFO and migraine. Although the results of uncontrolled observational studies suggest the PFO closure may have a beneficial effect on migraine frequency, a large randomized trial failed to support such a conclusion. Until there is more evidence from ongoing large controlled trials, PFO closure should not be performed in clinical practice for the prophylaxis of migraine.

Entities:  

Mesh:

Year:  2007        PMID: 17504652     DOI: 10.1007/s11916-007-0196-2

Source DB:  PubMed          Journal:  Curr Pain Headache Rep        ISSN: 1534-3081


  33 in total

Review 1.  Patent foramen ovale and migraine--bringing closure to the subject.

Authors:  Todd J Schwedt; David W Dodick
Journal:  Headache       Date:  2006-04       Impact factor: 5.887

2.  Potential source of cerebral embolism in migraine with aura: a transcranial Doppler study.

Authors:  G P Anzola; M Magoni; M Guindani; L Rozzini; G Dalla Volta
Journal:  Neurology       Date:  1999-05-12       Impact factor: 9.910

3.  Risk of ischemic complications related to the intensity of triptan and ergotamine use.

Authors:  E A Wammes-van der Heijden; H Rahimtoola; H G M Leufkens; C C Tijssen; A C G Egberts
Journal:  Neurology       Date:  2006-10-10       Impact factor: 9.910

4.  Effect on migraine of closure of cardiac right-to-left shunts to prevent recurrence of decompression illness or stroke or for haemodynamic reasons.

Authors:  P T Wilmshurst; S Nightingale; K P Walsh; W L Morrison
Journal:  Lancet       Date:  2000-11-11       Impact factor: 79.321

5.  Clinical and imaging findings in cryptogenic stroke patients with and without patent foramen ovale: the PFO-ASA Study. Atrial Septal Aneurysm.

Authors:  C Lamy; C Giannesini; M Zuber; C Arquizan; J F Meder; D Trystram; J Coste; J L Mas
Journal:  Stroke       Date:  2002-03       Impact factor: 7.914

6.  Relationship between migraine and cardiac and pulmonary right-to-left shunts.

Authors:  P Wilmshurst; S Nightingale
Journal:  Clin Sci (Lond)       Date:  2001-02       Impact factor: 6.124

7.  Clopidogrel reduces migraine with aura after transcatheter closure of persistent foramen ovale and atrial septal defects.

Authors:  P T Wilmshurst; S Nightingale; K P Walsh; W L Morrison
Journal:  Heart       Date:  2005-09       Impact factor: 5.994

8.  Percutaneous closure of patent foramen ovale reduces the frequency of migraine attacks.

Authors:  M Schwerzmann; S Wiher; K Nedeltchev; H P Mattle; A Wahl; C Seiler; B Meier; S Windecker
Journal:  Neurology       Date:  2004-04-27       Impact factor: 9.910

9.  Long-term efficacy of transcatheter patent foramen ovale closure on migraine headache with aura and recurrent stroke.

Authors:  Alessandro Giardini; Andrea Donti; Roberto Formigari; Luisa Salomone; Gualtiero Palareti; Donata Guidetti; Fernando Maria Picchio
Journal:  Catheter Cardiovasc Interv       Date:  2006-04       Impact factor: 2.692

10.  Prevalence of patent foramen ovale in a large series of patients with migraine with aura, migraine without aura and cluster headache, and relationship with clinical phenotype.

Authors:  Giorgio Dalla Volta; Massimiliano Guindani; Paola Zavarise; Simona Griffini; Alessandro Pezzini; Alessandro Padovani
Journal:  J Headache Pain       Date:  2005-09       Impact factor: 7.277

View more
  15 in total

Review 1.  Closure of patent foramen ovale in the prevention of migraine: not enough evidence in favor.

Authors:  Markus Schürks; Hans-Christoph Diener
Journal:  Nat Clin Pract Neurol       Date:  2008-12-02

Review 2.  Migraine in pregnancy.

Authors:  Peter J Goadsby; Jay Goldberg; Stephen D Silberstein
Journal:  BMJ       Date:  2008-06-28

3.  Prevalence of cardiac right left shunts in migraine: a population-based case-control study.

Authors:  Michael Küper; Kasja Rabe; Dagny Holle; Irini Savidou; Peter Dommes; Markus Frings; Hans Christoph Diener; Zaza Katsarava
Journal:  Neurol Sci       Date:  2012-02-25       Impact factor: 3.307

Review 4.  [Current diagnosis and treatment of migraine].

Authors:  H-C Diener; Z Katsarava; V Limmroth
Journal:  Schmerz       Date:  2008-02       Impact factor: 1.107

5.  Patent foramen ovale and migraine: a cross-sectional study from the Northern Manhattan Study (NOMAS).

Authors:  Tatjana Rundek; Mitchell S V Elkind; Marco R Di Tullio; Emmanuel Carrera; Zhezhen Jin; Ralph L Sacco; Shunichi Homma
Journal:  Circulation       Date:  2008-09-15       Impact factor: 29.690

6.  Patent foramen ovale detected by near-infrared spectroscopy in patients suffering from migraine with aura.

Authors:  William Liboni; Filippo Molinari; Giovanni Battista Allais; Ornella Mana; Emanuela Negri; Giovanni D'Andrea; Gennaro Bussone; Chiara Benedetto
Journal:  Neurol Sci       Date:  2008-05       Impact factor: 3.307

Review 7.  The diagnostic iter of patent foramen ovale in migraine patients: an update.

Authors:  William Liboni; Filippo Molinari; Amedeo Chiribiri; Gianni Allais; Ornella Mana; Emanuela Negri; Gianfranco Grippi; Massimiliano Giacobbe; Sergio Badalamenti; Chiara Benedetto
Journal:  Neurol Sci       Date:  2008-05       Impact factor: 3.307

8.  [Headache and migraine].

Authors:  H C Diener; M A Slomke; V Limmroth
Journal:  Nervenarzt       Date:  2007-09       Impact factor: 1.214

9.  Ischemic stroke subtypes and migraine with visual aura in the ARIC study.

Authors:  X Michelle Androulakis; Nishanth Kodumuri; Lauren D Giamberardino; Wayne D Rosamond; Rebecca F Gottesman; Eunsil Yim; Souvik Sen
Journal:  Neurology       Date:  2016-11-09       Impact factor: 9.910

10.  Pathophysiology of migraine.

Authors:  Peter J Goadsby
Journal:  Ann Indian Acad Neurol       Date:  2012-08       Impact factor: 1.383

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.